R. G. Borroni, “Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study”, Acta Derm Venereol, vol. 101, no. 11, p. adv00605, Nov. 2021.